Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Alcon Research

ClinicalTrials.gov lists Alcon Research as lead sponsor of 624 trials. It has 32 active development programs and 99 approved assets.

Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

69 0 1999 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 23 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 25 in 2026 and about 24 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Alcon Research: 624 lead-sponsored trials and 0 legal-entity registrations.

Get the Alcon Research report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (77)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Glaucoma 165
Cataract 138
Glaucoma, Open-Angle 118
Dry Eye Syndromes 114
Myopia 97

Trials by start year as sponsor or collaborator (28)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 23
2025 22
2024 30
2023 41
2022 22
2021 28
2020 23
2019 19
2018 23
2017 16

Prediction, not a registry value: median of 22 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 7 months across 577 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (32)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Latanoprost 0.005% Ophthalmic Solution Glaucoma, Open-Angle Phase 3 4
0.003% AR-15512 ophthalmic solution Dry Eye Syndromes Phase 3 3
Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution Glaucoma Phase 3 2
Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution Glaucoma, Open-Angle Phase 3 2
Aflibercept ophthalmic solution Neovascularization, Pathologic Phase 3 2

Approved assets (99)

Shown in this order: max phase first.

Approved assets
Drug Trials
Travoprost 19
Co-Latanoprost 11
Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension 11
Olopatadine Hydrochloride Ophthalmic Solution 0.2% 9
SYSTANE® ULTRA Lubricant Eye Drops 8

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
55% hit target (n=91) 65% on time (n=84)

Journals published in (63)

Shown in this order: most published in first.

Journals published in
Journal Publications
American journal of ophthalmology 23
Ophthalmology 23
Investigative ophthalmology & visual science 18
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 17
Journal of cataract and refractive surgery 17

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
348 0 2019-11-19

Organization relationships (1)

Organization relationships
Related organization Relationship Evidence
PPD Development, LP Uses vendor 1

Latest dated events (1,123)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-24 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (178)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
AATF Trial sponsor Named in trial inclusion criteria
AATF Trial collaborator Named in trial inclusion criteria
ACD Trial collaborator Named in trial inclusion criteria
BAK1 Trial sponsor Named in trial inclusion criteria
BAK1 Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.